Development of an enzyme-linked immunosorbent assay for chenodeoxycholic acid using an anti-chenodeoxycholic acid monoclonal antibody

• Published in: Analytical methods Vol. 7; no. 11; pp. 4583 - 4589
• Main Authors: Zhang, Yue, Qu, Huihua, Feng, Huibin, Wang, Xueqian, Shan, Wenchao, Zeng, Wenhao, Wang, Qingguo, Zhao, Yan
• Format: Journal Article
• Language: English
• Published: 01.01.2015
• Subjects: Assaying; Biotechnology; Conjugates; Mathematical analysis; Medicine; Monoclonal antibodies; Reproducibility; Standard deviation
• ISSN: 1759-9660; 1759-9679
• DOI: 10.1039/c5ay00733j

CDCA is one of the major bile acids in humans and has important clinical significance and therapeutic applications. In this work, a new monoclonal antibody (MAb) specific for chenodeoxycholic acid (CDCA) was prepared and characterized. A hybridoma secreting an anti-CDCA MAb was produced by fusing splenocytes from a mouse immunized against a CDCA-BSA conjugate with the hypoxanthine-aminopterin-thymidine (HAT)-sensitive mouse myeloma cell line Sp2/0-Ag14. The antibody was highly specific for CDCA, exhibited only weak reactions with CA and DCA and did not react with other structurally related chemicals. Subsequently, a MAb-based enzyme-linked immunosorbent assay (ELISA) against CDCA was developed and characterized. In this assay, we detected an effective CDCA measurement range of 32 ng mL −1 to 1024 ng mL −1 ( R 2 = 0.9962). Both intra-assay and inter-assay repeatability and precision were achieved with relative standard deviations (RSD) below 10%. Additionally, the CDCA levels in medicines and samples were determined with high sensitivity and efficiency. This study provides a useful method for detecting CDCA in medicines and will contribute to the further clinical research. The icELISA for CDCA using anti-CDCA MAb will be of great use in determining CDCA in medicines for safe medications and may provide a potential tool for clinical tests.